文献速递核素与放射性配体治疗

单时间点成像用于[177Lu]Lu-DOTATATE治疗后剂量测定:现有方法的准确性及降低时间点选择敏感性的新型数据驱动模型

Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.
PubMed 文献 · J Nucl Med · 2023-07-27

该研究基于27例患者第1周期[177Lu]Lu-DOTATATE治疗后4个时间点的SPECT/CT数据(100个肿瘤和54个肾脏),构建数据驱动回归模型以减少时间整合活度(TIA)估计对时间点选择的敏感性,并与常用单时间点方法比较。结果显示第3-5天所有方法MAE均小于7%,其他时间点Madsen法和数据驱动模型1、2表现较好(肾脏MAE<17%,肿瘤MAE<32%),而Hänscheid法误差明显更高;在最早时间点加入基线生物标志物的模型表现优于仅依赖单次活度测量的方法。

要点

  • 第3-5天所有评估的单时间点方法表现良好,肾脏和肿瘤MAE均小于7%。
  • 其他时间点Madsen法和数据驱动模型1、2的MAE为肾脏<17%、肿瘤<32%,Hänscheid法误差明显更高。
  • 在最早时间点(3-5小时),加入基线生物标志物的模型对肾脏TIA估计的MAE±SD从15.6%±1.3%降至11.8%±1.0%。

核心结论

  • Madsen法和所提出的数据驱动模型对时间点选择的敏感性低于Hänscheid法。
  • 在最具实践性的最早时间点,纳入基线生物标志物的模型优于仅依赖单次活度测量的其他方法。

研究设计与样本

  • 研究纳入27例患者第1周期[177Lu]Lu-DOTATATE治疗后于4个时间段行SPECT/CT,共分析100个分割肿瘤和54个肾脏。
  • 构建单时间点预测表达式TIA = A(t) × g(t)(模型1),其中g(t)通过非参数广义加性模型以最小化相对于4时间点SPECT参考TIA的归一化均方误差来估计。
  • 模型2在单次活度测量基础上纳入基线生物标志物作为辅助数据,拟合广义加性模型。
  • 采用留一交叉验证,以预测TIA与参考TIA之间的平均绝对误差(MAE)和均方误差评估单时间点模型。
  • 使用临床相关的时间-活度模拟在500例虚拟患者上评估,表现相似。

主要发现

  • 在第3-5天,所有评估的单时间点方法表现很好,肾脏和肿瘤的MAE均小于7%(患者间SD<10%)。
  • 在其他时间点,Madsen法和数据驱动模型1、2表现尚可(肾脏MAE<17%,肿瘤MAE<32%),而Hänscheid法误差明显更高。
  • 加入基线生物标志物在最早时间点(3-5小时)显示中度增强,尤其对肾脏TIA估计,MAE±SD从15.6%±1.3%降至11.8%±1.0%。
  • 使用临床相关时间-活度模拟在500例虚拟患者上的评估显示相似表现。

关键数值与推荐

  • 第3-5天所有评估的单时间点方法:肾脏和肿瘤MAE均小于7%,患者间SD<10%。
  • 其他时间点:Madsen法和数据驱动模型1、2的MAE为肾脏<17%、肿瘤<32%;Hänscheid法误差明显更高。
  • 最早时间点(3-5小时)加入基线生物标志物后肾脏TIA估计的MAE±SD从15.6%±1.3%降至11.8%±1.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Estimation of the time-integrated activity (TIA) for dosimetry from imaging at a single time point (STP) facilitates the clinical translation of dosimetry-guided radiopharmaceutical therapy. However, the accuracy of the STP methods for TIA estimation varies on the basis of time-point selection. We constructed patient data-driven regression models to reduce the sensitivity to time-point selection and to compare these new models with commonly used STP methods. Methods: SPECT/CT performed at time period (TP) 1 (3-5 h), TP2 (days 1-2), TP3 (days 3-5), and TP4 (days 6-8) after cycle 1 of [177Lu]Lu-DOTATATE therapy involved 27 patients with 100 segmented tumors and 54 kidneys. Influenced by the previous physics-based STP models of Madsen et al. and Hänscheid et al., we constructed an STP prediction expression, TIA = A(t) × g(t), in a SPECT data-driven way (model 1), in which A(t) is the observed activity at imaging time t, and the curve, g(t), is estimated with a nonparametric generalized additive model by minimizing the normalized mean square error relative to the TIA derived from 4-time-point SPECT (reference TIA). Furthermore, we fit a generalized additive model that incorporates baseline biomarkers as auxiliary data in addition to the single activity measurement (model 2). Leave-one-out cross validation was performed to evaluate STP models using mean absolute error (MAE) and mean square error between the predicted and reference TIA. Results: At days 3-5, all evaluated STP methods performed very well, with an MAE of less than 7% (between-patient SD of <10%) for both kidneys and tumors. At other TPs, the Madsen method and data-driven models 1 and 2 performed reasonably well (MAEs < 17% for kidneys and < 32% for tumors), whereas the error with the Hänscheid method was substantially higher. The proof of concept of adding baseline biomarkers to the prediction model was demonstrated and showed a moderate enhancement at TP1, especially for estimating kidney TIA (MAE ± SD from 15.6% ± 1.3% to 11.8% ± 1.0%). Evaluations on 500 virtual patients using clinically relevant time-activity simulations showed a similar performance. Conclusion: The performance of the Madsen method and proposed data-driven models is less sensitive to TP selection than is the Hänscheid method. At the earliest TP, which is the most practical, the model incorporating baseline biomarkers outperforms other methods that rely only on the single activity measurement.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang C, Peterson AB, Wong KK, et al. Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection. J Nucl Med. 2023. PMID: 37500260. doi:10.2967/jnumed.122.265338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。